Latest Commercial Partnerships News

Bio-Gene Technology is progressing critical toxicology studies for Flavocide with a targeted APVMA submission in March 2027, while forging a strategic partnership to launch Qcide insecticides in Japan by late 2026.

Connexion Mobility reported a record $3 million quarterly revenue, boosted by exclusive software deployment for GM Canada’s Enhanced Exposure Program, while net profit before tax fell 31% due to higher expenses.

ION Video has entered substantive early-stage discussions with Meta and Alphabet, exploring potential applications of its patented video virtualization technology. These talks are part of a broader engagement with major global tech players, though no formal deals have yet been struck.

Sparc Technologies has secured a $680,000 non-dilutive advance on its anticipated FY26 R&D tax refund, strengthening its cash flow as it accelerates commercialisation of its graphene additive ecosparc and green hydrogen ventures.

Nanoveu Limited showcased its cutting-edge EMASS semiconductor technology at the Pitt Street Research Semiconductor Conference 2026, spotlighting its ultra-low-power AI chips designed for next-gen smart devices and drones.

Sparc Technologies has formalised a collaboration with HydroGraph Clean Power to test and potentially commercialise graphene-enhanced additives for protective coatings, aiming to revolutionise corrosion protection.

EVE Health Group has increased its placement funding to $1.3 million, backed by a cornerstone investor with pharmaceutical expertise, advancing its reformulated drug programs targeting billion-dollar global markets.

Lynas Rare Earths and Japan Australia Rare Earths B.V. have extended their supply agreement to 2038, securing firm commitments for critical rare earths with a pricing floor and upside sharing mechanism.

Audeara Limited has initiated three new white-label Auracast™ programs with Clinico Inc., alongside launching its BT-03 Audio Broadcaster in Australia, marking a significant step in scaling its audio technology globally.

Nimy Resources has addressed a recent spike in its share price and trading volume, attributing the movement to its Managing Director's U.S. trade mission and the release of a commissioned research article.

Avecho Biotechnology has completed recruitment for the interim analysis cohort of its pivotal Phase III trial for a CBD insomnia treatment, with results expected in June 2026. This milestone could significantly de-risk the program and unlock major market opportunities.

Merino & Co. Limited reported a 60.5% drop in revenue and a 28.2% increase in net loss for the half-year ending December 2025, reflecting a strategic investment phase aimed at future growth. The company is expanding production capacity and building inventory ahead of wholesale expansion, signaling a pivot towards revenue acceleration.